术中地塞米松不增加术后伤口感染风险:ENIGMA-II试验倾向评分匹配事后分析
该研究为ENIGMA-II试验的事后分析,纳入5499例非心脏手术患者,采用倾向评分逆概率加权评估术中地塞米松与术后感染等安全性结局的关联。结果显示地塞米松组伤口感染、严重术后恶心呕吐、恢复质量评分、PACU停留时间及主要结局均无显著差异,且发热减少、住院时间缩短,提示在高危非心脏手术患者中地塞米松不增加术后30天内伤口感染等不良事件风险。
要点
- 术中地塞米松不增加术后伤口感染风险(RR 1.10,95%CI 0.89-1.34,P=0.38)。
- 地塞米松与发热减少(RR 0.61,95%CI 0.5-0.74,P<0.001)和住院时间缩短相关。
- 无论是否合并糖尿病或伤口污染状态,地塞米松的安全性结论一致。
核心结论
- 高危非心脏手术患者术中给予地塞米松不增加术后30天内伤口感染或其他不良事件风险,在合并或不合并糖尿病患者中均似安全。
研究设计与样本
- ENIGMA-II试验的事后分析,纳入7112例非心脏手术受试者中的5499例,采用估计倾向评分的逆概率加权法评估地塞米松与术后感染、恢复质量及不良安全结局的关联。
主要发现
- 地塞米松用于5499例分析对象中的2178例(40%),伤口感染发生率地塞米松组189例(8.7%)vs 非地塞米松组275例(8.3%),倾向评分校正相对风险(RR)1.10,95%置信区间(CI)0.89-1.34,P=0.38。
- 术后第1天严重术后恶心呕吐发生率242例(7.3%)vs 189例(8.7%),倾向评分校正RR 1.06,95%CI 0.86-1.30,P=0.59。
- 恢复质量评分中位数14(四分位距12-15)vs 中位数14(四分位距12-16),P=0.10;麻醉后监护室停留时间倾向评分校正中位数(四分位距)2.0(1.3, 2.9)vs 1.9(1.3, 3.1),P=0.60。
- 地塞米松与第1-3天发热减少相关:182例(8.4%)vs 488例(14.7%),RR 0.61,95%CI 0.5-0.74,P<0.001;并与住院时间缩短相关:倾向评分校正中位数(四分位距)5.0(2.9, 8.2)vs 5.3(3.1, 9.1),P<0.001。
- 糖尿病和手术伤口污染状态均未改变上述结局。
临床怎么用
- 在高危非心脏手术患者中,术中地塞米松可用于减少发热和缩短住院时间,而不增加术后伤口感染风险。
- 对于合并糖尿病或伤口污染的患者,地塞米松的安全性结论同样适用,无需因感染顾虑而避免使用。
局限性
- 本研究为ENIGMA-II试验的事后分析,非预设主要分析,结论需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In a post hoc analysis of the ENIGMA-II trial, we sought to determine whether intraoperative dexamethasone was associated with adverse safety outcomes. METHODS: Inverse probability weighting with estimated propensity scores was used to determine the association of dexamethasone administration with postoperative infection, quality of recovery, and adverse safety outcomes for 5499 of the 7112 non-cardiac surgery subjects enrolled in ENIGMA-II. RESULTS: Dexamethasone was administered to 2178 (40%) of the 5499 subjects included in this analysis and was not associated with wound infection [189 (8.7%) vs 275 (8.3%); propensity score-adjusted relative risk (RR) 1.10; 95% confidence interval (CI) 0.89-1.34; P=0.38], severe postoperative nausea and vomiting on day 1 [242 (7.3%) vs 189 (8.7%); propensity score-adjusted RR 1.06; 95% CI 0.86-1.30; P=0.59], quality of recovery score [median 14, interquartile range (IQR) 12-15, vs median 14, IQR 12-16, P=0.10), length of stay in the postanaesthesia care unit [propensity score-adjusted median (IQR) 2.0 (1.3, 2.9) vs 1.9 (1.3, 3.1), P=0.60], or the primary outcome of the main trial. Dexamethasone administration was associated with a decrease in fever on days 1-3 [182 (8.4%) vs 488 (14.7%); RR 0.61; 95% CI 0.5-0.74; P<0.001] and shorter lengths of stay in hospital [propensity score-adjusted median (IQR) 5.0 (2.9, 8.2) vs 5.3 (3.1, 9.1), P<0.001]. Neither diabetes mellitus nor surgical wound contamination status altered these outcomes. CONCLUSION: Dexamethasone administration to high-risk non-cardiac surgical patients did not increase the risk of postoperative wound infection or other adverse events up to day 30, and appears to be safe in patients either with or without diabetes mellitus. CLINICAL TRIAL REGISTRATION: NCT00430989.
引用
- Corcoran T, Kasza J, Short TG, et al. Intraoperative dexamethasone does not increase the risk of postoperative wound infection: a propensity score-matched post hoc analysis of the ENIGMA-II trial (EnDEX). Br J Anaesth. 2017. PMID: 28100522. doi:10.1093/bja/aew446
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。